SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Xenomics, Inc. on October 18, 2007, covering events that occurred on October 12, 2007. The registrant is a Florida corporation headquartered in New York. Note: The request metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing discloses a specific capital raise event but does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the period.
- Capital Raised: $700,000 in aggregate gross proceeds.
- Securities Issued: 1,400,000 shares of common stock.
- Warrants Issued: A five-year warrant to purchase 100,000 shares at an exercise price of $0.50 per share issued to a selling agent.
- Liquidity/Debt: The filing text does not provide a clear value for total debt, cash balances, or liquidity ratios outside of the proceeds from this transaction.
Material Changes
The primary material change is the entry into a Material Definitive Agreement and the unregistered sale of equity securities. The company closed a private placement with an overseas institutional investor. This transaction increased the company's cash position by $700,000 and expanded its outstanding share count by 1,400,000 shares plus the potential issuance of 100,000 shares via warrants.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the transaction. The sale was conducted under the exemption from registration provided by Section 4(2) of the Securities Act of 1933 and Regulation D.
Key Facts for Investor Verification
- Verify the identity of the "overseas institutional investor" and any potential conflicts of interest.
- Confirm the dilution impact of the 1,400,000 new shares and the 100,000 warrant shares on existing shareholders.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for covenants, redemption rights, or liquidation preferences not detailed in the summary.
- Check subsequent filings to determine how the $700,000 in proceeds was utilized.